Buscar
ProQR Therapeutics NV
PRQRAñadir a la lista de seguimiento
1.710USD
+0.010+0.59%
Cierre 09-24 16:00（ET）
227.41MCap. mercado
PérdidaP/E TTM
Acerca de ProQR Therapeutics NV Compañía
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Perfil de ProQR Therapeutics NV
Símbolo de cotizaciónPRQR
Nombre de la empresaProQR Therapeutics NV
Fecha de salida a bolsaSep 18, 2014
Director ejecutivode Boer (Daniel Anton)
Número de empleados166
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 18
DirecciónZernikedreef 9
CiudadLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 CK
Teléfono31881667000
Sitio Webhttps://www.proqr.com/
Símbolo de cotizaciónPRQR
Fecha de salida a bolsaSep 18, 2014
Director ejecutivode Boer (Daniel Anton)
Ejecutivos de ProQR Therapeutics NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Dr. Dinko Valerio, Ph.D.
Dr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. Dinko Valerio, Ph.D.
Dr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. Dinko Valerio, Ph.D.
Dr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
300.00K
+50.00%
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
300.00K
+50.00%
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
300.00K
+50.00%
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Dr. Dinko Valerio, Ph.D.
Dr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. Dinko Valerio, Ph.D.
Dr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. Dinko Valerio, Ph.D.
Dr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de ProQR Therapeutics NV?
Los cinco principales accionistas de ProQR Therapeutics NV son: Mr. Gerard Platenburg, Ph.D.
¿Cuántas instituciones poseen acciones de ProQR Therapeutics NV (PRQR)?
A fecha de 2026Q1, 122 instituciones poseen acciones de ProQR Therapeutics NV, con un valor de mercado combinado de aproximadamente 38.34M, lo que representa el 36.39% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -5670621.00.